Ceria (CeO2) particles with low to ultra-low loading of nickel dopant were produced using an aerosol-based, droplet-to-particle synthesis via an in-line calcination technique. This aerosol-based ...

The bioanalytical testing services market presents key opportunities in specialized testing for complex therapeutics, driven ...

Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

The sheer growth of small biotechs and mid‑sized pharma companies entering the field has reshaped expectations of Contract Development and Manufacturing Organisations (CDMOs).

The market is defying broader economic headwinds through a structural pivot toward high-complexity outsourcing. While general R&D spending has tightened, capital is aggressively flowing into ...

Researchers have developed an automated method for growing lung organoids, making the process more efficient. Organoids, clusters of cells that contain the same cell types as full-sized organs, offer ...

Please provide your email address to receive an email when new articles are posted on . The FDA issued draft guidance that would streamline testing of biosimilars. A separate plan would eliminate ...

The FDA's draft guidance could streamline biosimilar approval by reducing the need for comparative efficacy studies, emphasizing analytical assessments instead. This approach may lower development ...

Dianthus Therapeutics Inc. has joined the recent trend of companies licensing therapies in development from China. The company will pay as much as $1 billion to Nanjing Leads Biolabs Co. Ltd. for DNTH ...

Editor’s note: This story is part of Peak, The Athletic’s desk covering leadership, personal development and performance through the lens of sports. Follow Peak here. Joe Boylan worked in the NBA for ...

As an emerging 3D cell culture system, organoid technology has demonstrated substantial potential in basic research and translational medicine by recapitulating in vivo organ structures and functions.

Sept 29 (Reuters) - Kala Bio (KALA.O), opens new tab will stop developing its experimental treatment for a type of eye condition after it failed to meet the main goal in a mid-stage study, sending the ...